Entries by Admin

Trethera attending the 59th ASH Annual Meeting in Atlanta

November 27, 2017 – Trethera Corporation will be attending the American Society of Hematology (ASH) Annual Meeting in Atlanta from December 9-12, 2017. Trethera is preparing for initiation of a Phase 1 clinical trial in myelodysplastic syndrome (MDS) for its small molecule, deoxycytidine kinase inhibitor, TRE-515.

Trethera at BioPharm America

September 7, 2017 – Trethera, a biotechnology company developing innovative small molecule inhibitors of cancer nucleotide metabolism, will be attending the BioPharma America conference in Boston, MA, September 26-27, 2017.  

Trethera to attend RESI Boston 2017

September 7, 2017 – Trethera, a biotechnology company developing innovative small molecule inhibitors of cancer nucleotide metabolism, will be attending RESI Boston 2017 on September 26, 2017.

SOHO 2017 Annual Meeting

September 7, 2017 – Trethera will be attending the Society of Hematologic Oncology’s Annual Meeting, September 13-15, 2017, in Houston, Texas. For more information on Trethera’s attendance, please contact info@trethera.com

ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways

Abstract Leukemia cells rely on two nucleotide biosynthetic pathways, de novo and salvage, to produce dNTPs for DNA replication. Here, using metabolomic, proteomic, and phosphoproteomic approaches, we show that inhibition of the replication stress sensing kinase ataxia telangiectasia and Rad3-related protein (ATR) reduces the output of both de novo and salvage pathways by regulating the […]